Want to see IN:PFIZER full AI Analyst Report?
Top Page
PFIZER LIMITED
(PFIZER)
Select Model
Select Model
Rating:77Outperform
Price Target:
₹4,326.00
▼(-8.81% Downside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by strong financial durability (high profitability and very low leverage) and supportive trend/momentum indicators. The main constraint is valuation, with a higher P/E and only a modest dividend yield limiting the overall score.
Positive Factors
Very low leverage
Exceptionally low leverage reduces financial strain and preserves flexibility for research, investment, and capital returns. The improving debt-to-equity trend also strengthens resilience if operating conditions weaken, supporting a durable balance-sheet advantage over the next several quarters.
Negative Factors
Uneven revenue trajectory
The multi-year pattern shows that top-line growth has not been consistently durable, despite the recent rebound. Repeated revenue declines can make planning and investment less predictable and may require sustained execution to preserve the latest growth recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Exceptionally low leverage reduces financial strain and preserves flexibility for research, investment, and capital returns. The improving debt-to-equity trend also strengthens resilience if operating conditions weaken, supporting a durable balance-sheet advantage over the next several quarters.
Read all positive factors
PFIZER LIMITED (PFIZER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹174.36B
Dividend Yield1.97%
Average Volume (3M)3.19K
Price to Earnings (P/E)23.7
Beta (1Y)0.71
Revenue Growth10.69%
EPS Growth-9.09%
CountryIN
Employees1,244
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)160.69
Shares Outstanding45,747,730
10 Day Avg. Volume5,066
30 Day Avg. Volume3,187
Financial Highlights & Ratios
PEG Ratio-5.08
Price to Book (P/B)5.14
Price to Sales (P/S)8.57
P/FCF Ratio19.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)182.4
Revenue Forecast (FY)₹27.34B
PFIZER LIMITED Business Overview & Revenue Model
Company Description
Pfizer Limited operates as a pharmaceutical company, engaged in the development, promotion, sale, and international export of medicinal products. Its diverse product range addresses numerous therapeutic needs, such as those related to the neuro/ce...
How the Company Makes Money
PFIZER LIMITED makes money primarily by selling Pfizer-branded prescription medicines and vaccines to customers such as government and public health purchasers, hospitals and clinics, wholesalers/distributors, and retail pharmacies (directly or vi...
PFIZER LIMITED Earnings Call Summary
Earnings Call Date:Oct 28, 2024
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Positive
Pfizer's earnings call reflected a strong financial performance with solid revenue and EPS growth, driven by effective cost management and advancements in the R&D pipeline. However, challenges such as impacts from the IRA Medicare Part D redesign and ongoing geopolitical uncertainties pose potential risks.Positive Updates
Strong Revenue Growth
Pfizer recorded revenues of $14.7 billion for the second quarter, representing a 10% operational increase year-over-year.
Negative Updates
Impact of IRA Medicare Part D Redesign
An $825 million year-over-year unfavorable impact due to higher manufacturer discounts resulting from the IRA Medicare Part D redesign.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Revenue Growth
Pfizer recorded revenues of $14.7 billion for the second quarter, representing a 10% operational increase year-over-year.
Read all positive updates
Company Guidance
During Pfizer's Second Quarter 2025 Earnings Conference Call, the company provided updated guidance reflecting strong year-to-date performance. Specifically, Pfizer raised its adjusted diluted EPS guidance for the full year 2025, driven by productivity gains and strategic initiatives to expand margins. The company reported second-quarter revenues of $14.7 billion, a 10% operational increase, and adjusted diluted EPS of $0.78, surpassing expectations. Pfizer's robust operating margins were achieved amidst challenges such as an $825 million unfavorable impact from higher manufacturer discounts due to the IRA Medicare Part D redesign. Pfizer's non-COVID portfolio, including strong performers like the Vyndaqel family and Eliquis, contributed significantly to its solid financial outlook. The company maintained its full-year 2025 revenue guidance of $61 billion to $64 billion and adjusted its SI&A and R&D expense forecasts while expecting an adjusted effective tax rate of approximately 13%. Pfizer's strategic focus remains on enhancing R&D productivity, leveraging AI and digital capabilities, and optimizing capital allocation to create long-term shareholder value.PFIZER LIMITED Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.70B | 25.20B | 22.81B | 21.93B | 24.25B | 26.11B |
| Gross Profit | 14.50B | 12.10B | 14.66B | 13.95B | 15.47B | 16.58B |
| EBITDA | 10.58B | 10.43B | 7.42B | 6.39B | 8.10B | 8.37B |
| Net Income | 7.35B | 7.22B | 7.68B | 5.51B | 6.24B | 6.13B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 49.22B | 49.11B | 42.29B | 40.01B | 39.01B |
| Cash, Cash Equivalents and Short-Term Investments | 30.88B | 31.11B | 28.01B | 20.27B | 18.40B | 16.33B |
| Total Debt | 0.00 | 702.30M | 1.08B | 945.40M | 1.34B | 1.67B |
| Total Liabilities | -42.03B | 7.19B | 6.94B | 6.33B | 7.93B | 10.36B |
| Stockholders Equity | 42.03B | 42.03B | 42.17B | 35.96B | 32.07B | 28.64B |
Cash Flow | ||||||
| Free Cash Flow | 5.89B | 11.18B | 6.32B | 2.38B | 2.91B | 6.52B |
| Operating Cash Flow | 5.99B | 11.44B | 6.60B | 2.57B | 3.56B | 6.67B |
| Investing Cash Flow | -1.14B | -7.39B | -713.40M | -713.40M | -360.50M | -5.75B |
| Financing Cash Flow | -7.75B | -7.97B | -2.05B | -2.05B | -3.46B | -1.81B |
PFIZER LIMITED Technical Analysis
Negative
4743.95
Price Trends
4447.70
Negative
4482.97
Negative
4620.27
Negative
Market Momentum
-178.29
Negative
26.11
Positive
14.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PFIZER, the sentiment is Negative. The current price of 4743.95 is above the 20-day moving average (MA) of 3951.04, above the 50-day MA of 4447.70, and above the 200-day MA of 4620.27, indicating a bearish trend. The MACD of -178.29 indicates Negative momentum. The RSI at 26.11 is Positive, neither overbought nor oversold. The STOCH value of 14.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PFIZER.
PFIZER LIMITED Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹552.48B | 34.22 | ― | 2.02% | 6.29% | 11.18% | |
79 Outperform | ₹1.05T | 31.17 | ― | 2.22% | 1.85% | -37.51% | |
77 Outperform | ₹174.36B | 23.70 | ― | 1.97% | 10.69% | -9.09% | |
77 Outperform | ₹430.26B | 40.29 | ― | 2.24% | 5.75% | 12.41% | |
70 Outperform | ₹67.84B | 20.95 | ― | 4.18% | -8.88% | -10.68% | |
65 Neutral | ₹505.28B | 44.69 | ― | 0.65% | 17.57% | 46.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:PFIZER
PFIZER LIMITED
3,876.80
-1,564.61
-28.75%
IN:ABBOTINDIA
Abbott India Limited
25,800.35
-3,475.84
-11.87%
IN:CIPLA
Cipla Ltd
1,313.70
-235.65
-15.21%
IN:GLAND
Gland Pharma Ltd.
3,079.30
1,164.88
60.85%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,531.40
-151.50
-5.65%
IN:SANOFI
Sanofi India Limited
2,932.40
-1,637.34
-35.83%
PFIZER LIMITED Corporate Events
Pfizer Limited Confirms SEBI Compliance on Share Dematerialization for Q3 2026
Oct 9, 2026
Pfizer Limited has reported that its registrar and share transfer agent, KFin Technologies Limited, has certified compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 20...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.